Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arcutis Biotherapeutics Inc
ARQT
Healthcare
Biotechnology
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment...
of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ARQT)
New Post
View:
Posts & Comments
Threaded Posts
(89)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 27, 2024 2:15pm
Arcutis Announces Fourth Quarter and Full Year 2023 Financia
Breaking News: $ARQT Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateQ4 net product revenues for ZORYVE® (roflumilast) cream 0.3% were $13.5
...more
(89)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 16, 2024 10:30am
Trend Tracker for (ARQT)
Breaking News: $ARQT Trend Tracker for (ARQT)2024-02-16 07:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the
...more
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Jul 25, 2022 7:58am
KEY CATALYSTS MAKE ARCUTIS A MUST WATCH!
$ARQT Excited to share our latest article on Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a biopharmaceutical company developing novel treatments for dermatological diseases.
...more
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Jul 07, 2021 8:26am
5 PROMISING STOCKS IN ALOPECIA AREATA
5 PROMISING STOCKS IN ALOPECIA AREATA 1 In 5 Americans Are Losing Their Hair... More than 50 percent of women experience balding… By 50 years of age, about 85 percent of men are balding
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon